Ionis Pharmaceuticals IONS Acquired in-process research and development
Acquired in-process research and development at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Ionis Pharmaceuticals’s 10-K, filed February 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ionis Pharmaceuticals's acquired in-process research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ionis Pharmaceuticals's acquired in-process research and development?
- Ionis Pharmaceuticals (IONS) reported acquired in-process research and development of $228.9M in Q4 2025.
- How has Ionis Pharmaceuticals's acquired in-process research and development changed year-over-year?
- Ionis Pharmaceuticals's acquired in-process research and development increased by 1.6% year-over-year, from $225.38M to $228.9M.
- What is the long-term trend for Ionis Pharmaceuticals's acquired in-process research and development?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's acquired in-process research and development has grown at a 0.9% compound annual growth rate (CAGR), from $899.63M to $915.62M.
- What does acquired in-process research and development mean?
- Cash spent to acquire research and development projects from other companies.
- How do you interpret acquired in-process research and development?
- Higher spending suggests an aggressive inorganic growth strategy, while lower spending may indicate a focus on internal R&D or capital preservation.
- How does acquired in-process research and development compare across companies?
- Common in biotech and pharma sectors where companies frequently acquire early-stage assets.